Novo Nordisk A/S
News
(4)April 2026
Novo Nordisk's etavopivat significantly reduces SCD crises in Phase 3 data
# 📄 What This Document Is ✨ This document is a Form 6-K, which is a report filed with the U.S. Securities and Exchange Commission (SEC) by a foreign private issuer (Novo Nordisk). 📄 Think of this as a major public announcement that provides critical updates to investors about a key drug candidate.
Novo Nordisk repurchases stock, confirming DKK 3.1 billion spent
# 📰 What This Document Is 📜 This filing is a Form 6-K, which is a report used by foreign private issuers—companies that list shares in the U.S. but are headquartered elsewhere—to provide updates on material events. Since Novo Nordisk is a Danish company, the 6-K acts like a formal announcement to
NOVO NORDISK A S — 6-K Filing
# 📄 What This Document Is This is a **Form 6-K** filing with the U.S. Securities and Exchange Commission (SEC). It's a routine report from a foreign company (Novo Nordisk, based in Denmark) to update American investors on a specific, important action: the progress of its share buyback program. 👉
March 2026
NOVO NORDISK A S — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a standard report that foreign companies like Novo Nordisk file with the U.S. SEC to keep American investors informed. This specific report is a routine update on their ongoing share buyback program. 👉 In simple terms: It’s a public receipt showin